The IV delivery of an AAV9 based gene replacement therapy using the Mecp2 knockout model of Rett syndrome improved survival in the treated cohort compared to the untreated Mecp2-null mice, despite relatively low levels of neuronal transduction (2–4%) [95]. The gene discussed is MECP2; the disease is atypical Rett syndrome.